After years of collaboration, Becton Dickinson is buying out San Jose, CA's Alverix, deepening its holdings in point-of-care testing and expanding its palette of diagnostics technology.
New Jersey startup Tyrx is now a part of Medtronic, as the world's largest medical device company has traded $160 million for the company and its line of FDA-cleared products designed to prevent implant-related infection.
Thermo Fisher reached a major milestone in its $13.6 billion bid to buy Life Technologies, announcing that it will sell its gene modulation, cell culture and magnetic beads segments to GE Healthcare for $1.06 billion. Thermo inked the deal after the European Commission said in November it would only approve the Life Tech merger if Thermo sold off some businesses.
GE Healthcare is expanding its footprint in the life sciences industry, snapping up the cell culture, gene modulation and magnetic bead business of Thermo Fisher Scientific for a bit more than a billion dollars. GE plans to add the technologies to its life sciences unit.
Industry analysts can't help but handicap which drugmakers will be the next target of heated industry M&A interest. So three days into the new year, they are putting their money on Jazz Pharmaceuticals, the Ireland-based company that has itself been in acquisition mode.
Ireland-based biopharma companies are all the rage these days. Blessed by advantageous tax laws, Elan and Warner Chilcott fell to takeover bids. And now that Jazz Pharmaceuticals has been bolstered by the addition of Gentium's rare-disease drug portfolio, it's back on the hit list of most likely takeover targets.
The U.K.'s Cyprotex has picked up competitor CeeTox in a deal worth up to $5.1 million, boosting its offerings in in vitro testing and expanding into cosmetics and personal care.
AtriCure has closed its deal for California's Estech, handing over $34 million to get its hands on some new surgical ablation technologies.
Despite a tumultuous 2013, Wright Medical's shares finished out the year at a 52-week high, a sign of confidence in its oft-redrawn mission statement and its odds of being acquired.
CareFusion has bagged up U.S. and Chinese approval for its $500 million deal for GE Healthcare's Vital Signs segment, closing in on a broader share of the market for anesthesia devices and disposables.